BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14:22-31. [PMID: 27729659 DOI: 10.1038/nrgastro.2016.155] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Magro F, Rocha C, Vieira AI, Sousa HT, Rosa I, Lopes S, Carvalho J, Dias CC, Afonso J. The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels. Therap Adv Gastroenterol 2018;11:1756284818796956. [PMID: 30263065 DOI: 10.1177/1756284818796956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 de Ridder L, Assa A, Bronsky J, Romano C, Russell RK, Afzal NA, Hauer AC, Knafelz D, Lionetti P, Strisciuglio C, Veres G, Winter H, Wolters VM, Sladek M, Vulto AG, Dias JA; Paediatric IBD Porto group of ESPGHAN. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr 2019;68:144-53. [PMID: 30169454 DOI: 10.1097/MPG.0000000000002141] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
3 Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 [DOI: 10.12998/wjcc.v9.i36.11285] [Reference Citation Analysis]
4 Scott FI, Lichtenstein GR. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Curr Treat Options Gastroenterol 2018;16:147-64. [PMID: 29492747 DOI: 10.1007/s11938-018-0177-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
5 Tapete G, Bertani L, Pieraccini A, Lynch EN, Giannotta M, Morganti R, Biviano I, Naldini S, Mumolo MG, De Nigris F, Calella F, Bagnoli S, Minciotti M, Maltinti S, Rentini S, Ceccarelli L, Lionetti P, Milla M, Costa F. Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. Inflamm Bowel Dis 2021:izab027. [PMID: 33570142 DOI: 10.1093/ibd/izab027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Parrish RH. Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights 2021;12:293-301. [DOI: 10.3390/gastroent12030026] [Reference Citation Analysis]
7 Afonso J, de Sousa HT, Rosa I, Carvalho J, Dias CC, Magro F. Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. Therap Adv Gastroenterol 2017;10:661-71. [PMID: 28932268 DOI: 10.1177/1756283X17722915] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Queiroz NSF, Saad-Hossne R, FrÓes RSB, Penna FGCE, Gabriel SB, Martins AL, Teixeira FV. DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arq Gastroenterol 2020;57:232-43. [PMID: 32935741 DOI: 10.1590/S0004-2803.202000000-45] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
9 Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A, Leone S, Previtali E, Aloi M, Alvisi P, Antonelli E, Ardizzone S, Astegiano M, Baldoni M, Beltrami M, Biancone L, Bodini G, Buda A, Bossa F, Bracci F, Calabrese E, Cappello M, Castiglione F, Ciacci C, Cicala M, Ciccocioppo R, Comberlato M, Cortelezzi CC, Cosintino R, Costa F, Costantino G, Cucchiara S, Cuomo A, D’incà R, Di Paolo MC, Di Sabatino A, Di Sario A, Frieri G, Fries W, Gasbarrini A, Geccherle A, Gionchetti P, Graziani MG, Grossi L, Guidi L, Imperiali G, Latella G, Lionetti P, Inserra G, Maconi G, Manguso F, Marino M, Mastronardi M, Mazzuoli S, Meucci G, Mendolaro M, Milla M, Mocci G, Monteleone G, Bortoluzzi FN, Pagnini C, Pastorelli L, Pica R, Piergallini S, Privitera A, Renna S, Ribaldone DG, Ricci C, Rispo A, Rocca R, Romano C, Romano M, Russo G, Sablich R, Saibeni S, Savarino E, Scribano ML, Spagnuolo R, Stasi E, Terpin MM, Testa A, Valpiani D, Variola A, Vernia P, Vitale G, Zoli G. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2019;51:632-9. [DOI: 10.1016/j.dld.2019.02.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
10 Danese S, Bonovas S, Peyrin-biroulet L. Positioning Ustekinumab in Crohn’s Disease: From Clinical Evidence to Clinical Practice. Journal of Crohn's and Colitis 2017;11:1258-66. [DOI: 10.1093/ecco-jcc/jjx079] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Danese S, D'Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis 2018;24:2106-12. [PMID: 29697791 DOI: 10.1093/ibd/izy076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
12 Pillai N, Dusheiko M, Maillard MH, Rogler G, Brüngger B, Bähler C, Pittet VEH; Swiss IBD Cohort Study Group . The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years. J Crohns Colitis 2019;13:744-54. [PMID: 30916775 DOI: 10.1093/ecco-jcc/jjz003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
13 Declerck P, Danesi R, Petersel D, Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs 2017;77:671-7. [PMID: 28258517 DOI: 10.1007/s40265-017-0717-1] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
14 Sonboli R, Najafi Z, Zarezadeh N, Yazdani M, Behrouz H. Improving SDS-PAGE method for monoclonal antibodies: The advantages of Tris-Acetate over Tris-Glycine SDS-PAGE system and comparison with CE-SDS method. Protein Expr Purif 2021;182:105845. [PMID: 33596474 DOI: 10.1016/j.pep.2021.105845] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
16 Pouillon L, Socha M, Demore B, Thilly N, Abitbol V, Danese S, Peyrin-Biroulet L. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol 2018;14:739-49. [PMID: 30118338 DOI: 10.1080/1744666X.2018.1512406] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 10.3] [Reference Citation Analysis]
17 Gimeno-Gracia M, Gargallo-Puyuelo CJ, Gomollón F. Bioequivalence studies with anti-TNF biosimilars. Expert Opin Biol Ther 2019;19:1031-43. [PMID: 30574813 DOI: 10.1080/14712598.2019.1561851] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Peyrin-biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T. Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach. Expert Review of Gastroenterology & Hepatology 2019;13:731-8. [DOI: 10.1080/17474124.2019.1645595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
19 Farkas K, Molnár T. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease. Immunotherapy 2018;10:107-17. [PMID: 29124994 DOI: 10.2217/imt-2017-0107] [Reference Citation Analysis]
20 Park SH, Park JC, Lukas M, Kolar M, Loftus EV. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. Intest Res 2020;18:34-44. [PMID: 32013313 DOI: 10.5217/ir.2019.09147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. J Crohns Colitis. 2017;11:26-34. [PMID: 27927718 DOI: 10.1093/ecco-jcc/jjw198] [Cited by in Crossref: 130] [Cited by in F6Publishing: 108] [Article Influence: 21.7] [Reference Citation Analysis]
22 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
23 Bonovas S, Peyrin-biroulet L, Danese S. Infliximab biosimilar CT-P13 for inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2018;3:373-5. [DOI: 10.1016/s2468-1253(18)30116-x] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Pillai N, Dusheiko M, Burnand B, Pittet V. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500. [PMID: 28973005 DOI: 10.1371/journal.pone.0185500] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 11.2] [Reference Citation Analysis]
25 Magro F, Dias CC, Portela F, Miranda M, Fernandes S, Bernardo S, Ministro P, Lago P, Rosa I, Pita I, Correia L, Rodrigues PP; GEDII [Portuguese IBD Group]. Development and Validation of Risk Matrices Concerning Ulcerative Colitis Outcomes-Bayesian Network Analysis. J Crohns Colitis 2019;13:401-9. [PMID: 30329032 DOI: 10.1093/ecco-jcc/jjy168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
26 Null K, Kumar V, Lissoos T, Luo M. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease. Journal of Medical Economics 2018;21:1102-9. [DOI: 10.1080/13696998.2018.1511568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Radin M, Sciascia S, Roccatello D, Cuadrado MJ. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. BioDrugs. 2017;31:37-49. [PMID: 28035633 DOI: 10.1007/s40259-016-0206-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
28 Edwards CJ, Hercogová J, Albrand H, Amiot A. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther 2019;19:1001-14. [PMID: 31056970 DOI: 10.1080/14712598.2019.1610381] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
29 Bonovas S, Peyrin-biroulet L, Danese S. Clinical development of biologicals and biosimilars - safety concerns. Expert Review of Clinical Pharmacology 2017;10:567-9. [DOI: 10.1080/17512433.2017.1293522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
30 Kabir ER, Moreino SS, Sharif Siam MK. The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy. Biomolecules 2019;9:E410. [PMID: 31450637 DOI: 10.3390/biom9090410] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
31 Buchner AM, Schneider Y, Lichtenstein GR. Biosimilars in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:45-56. [DOI: 10.14309/ajg.0000000000000844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Rencz F, Gulácsi L, Péntek M, Gecse KB, Dignass A, Halfvarson J, Gomollón F, Baji P, Peyrin-Biroulet L, Lakatos PL, Brodszky V. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert Rev Pharmacoecon Outcomes Res 2017;17:597-606. [PMID: 28434387 DOI: 10.1080/14737167.2017.1322509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
33 Cazap E, Jacobs I, McBride A, Popovian R, Sikora K. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. Oncologist 2018;23:1188-98. [PMID: 29769386 DOI: 10.1634/theoncologist.2017-0671] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
34 AlRuthia Y, Almadi M, Aljebreen A, Azzam N, Alsharif W, Alrasheed H, Almuaythir G, Saeed M, HajkhderMullaissa B, Alharbi O. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia. J Med Econ 2020;23:1102-10. [PMID: 32619388 DOI: 10.1080/13696998.2020.1791889] [Reference Citation Analysis]
35 D'Amico F, Solitano V, Peyrin-Biroulet L, Danese S. Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next? Expert Opin Biol Ther 2021;21:47-55. [PMID: 32857634 DOI: 10.1080/14712598.2020.1817374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Honavar SG. From Biologics to Biosimilars and Biobetters - Democratization of High-end Therapeutics. Indian J Ophthalmol 2021;69:207-8. [PMID: 33463558 DOI: 10.4103/ijo.IJO_150_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lovisa S, Genovese G, Danese S. Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease. J Crohns Colitis. 2019;13:659-668. [PMID: 30520951 DOI: 10.1093/ecco-jcc/jjy201] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
38 Ditani AS, Mallick PP, Anup N, Tambe V, Polaka S, Sengupta P, Rajpoot K, Tekade RK. Biosimilars accessible in the market for the treatment of cancer. J Control Release 2021;336:112-29. [PMID: 34126171 DOI: 10.1016/j.jconrel.2021.06.014] [Reference Citation Analysis]
39 Colloca L, Panaccione R, Murphy TK. The Clinical Implications of Nocebo Effects for Biosimilar Therapy. Front Pharmacol. 2019;10:1372. [PMID: 31849647 DOI: 10.3389/fphar.2019.01372] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
40 Gisbert JP, Chaparro M. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. Gastroenterol Hepatol 2018;41:389-405. [PMID: 29753532 DOI: 10.1016/j.gastrohep.2018.04.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
41 Garcia KS, Facas BP, Machado MB, Teixeira FV, Avedano L, Lönnfors S, Hossne RS, Peyrin-Biroulet L, Queiroz NSF. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients. Therap Adv Gastroenterol 2021;14:17562848211013249. [PMID: 34046083 DOI: 10.1177/17562848211013249] [Reference Citation Analysis]
42 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? J Crohns Colitis 2018;12:105-19. [PMID: 28961959 DOI: 10.1093/ecco-jcc/jjx117] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
44 Saito S, Nakazawa K, Suzuki K, Ishikawa T, Akazawa K. Paradigm Shift of Healthcare Cost for Patients with Inflammatory Bowel Diseases: A Claims Data-Based Analysis in Japan. GastrointestDisord 2018;1:120-8. [DOI: 10.3390/gidisord1010009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
45 Milassin Á, Fábián A, Molnár T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therap Adv Gastroenterol 2019;12:1756284819842748. [PMID: 31019554 DOI: 10.1177/1756284819842748] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
46 Danese S, Peyrin-biroulet L. To switch or not to switch: that is the biosimilar question. Nat Rev Gastroenterol Hepatol 2017;14:508-9. [DOI: 10.1038/nrgastro.2017.86] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
47 Blandizzi C, Galeazzi M, Valesini G. Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges. Pharmacological Research 2018;128:306-14. [DOI: 10.1016/j.phrs.2017.10.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
48 Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L. Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther 2018;47:773-83. [PMID: 29349829 DOI: 10.1111/apt.14514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Al Sulais E, AlAmeel T. Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease. Biologics 2020;14:1-11. [PMID: 32021084 DOI: 10.2147/BTT.S236433] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Macaluso FS, Leone S, Previtali E, Ventimiglia M, Armuzzi A, Orlando A; AMICI (Italian Inflammatory Bowel Disease Patients' Association) and IG-IBD (Italian Group for the Study of Inflammatory Bowel Disease). Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. Dig Liver Dis 2020;52:1304-9. [PMID: 32807691 DOI: 10.1016/j.dld.2020.07.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
51 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 2018;19:E2244. [PMID: 30065229 DOI: 10.3390/ijms19082244] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
52 Pouillon L, Allocca M, Peyrin-Biroulet L. Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Aliment Pharmacol Ther 2018;48:574-5. [PMID: 30156324 DOI: 10.1111/apt.14847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Pouillon L, Danese S, Hart A, Fiorino G, Argollo M, Selmi C, Carlo-Stella C, Loeuille D, Costanzo A, Lopez A, Vegni E, Radice S, Gilardi D, Socha M, Fazio M, González-Lorenzo M, Bonovas S, Magro F, Peyrin-Biroulet L. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. Aliment Pharmacol Ther 2019;49:1181-7. [PMID: 30932219 DOI: 10.1111/apt.15223] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
54 Dranitsaris G, Jacobs I, Kirchhoff C, Popovian R, Shane LG. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. Clinicoecon Outcomes Res 2017;9:573-84. [PMID: 29033595 DOI: 10.2147/CEOR.S140063] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
55 Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology 2020; 158: 1554-1573. e12. [PMID: 31926171 DOI: 10.1053/j.gastro.2020.01.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 27.5] [Reference Citation Analysis]
56 AlRuthia Y, Alharbi O, Aljebreen AM, Azzam NA, Almadi MA, Bahari OH, Almalki KA, Atham AT, Alanazi AS, Saeed M, HajkhderMullaissa B, Alsenaidy M, Balkhi B. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia. Cost Eff Resour Alloc 2019;17:25. [PMID: 31827409 DOI: 10.1186/s12962-019-0194-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
57 Jentzer A, Berger A, Labetoulle R, Haccourt A, Roblin X, Paul S. Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar. Therapeutic Drug Monitoring 2018;40:749-53. [DOI: 10.1097/ftd.0000000000000565] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]